Advertisement RainDance Technologies launches solution for rare cancer mutation detection - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

RainDance Technologies launches solution for rare cancer mutation detection

RainDance Technologies, a provider of microdroplet-based single molecule and single cell analysis solutions, is launching its DeepSeq FFPE Solution, an end-to-end workflow for the ultra-deep targeted sequencing of Formalin-Fixed Paraffin-Embedded (FFPE) and fresh frozen tissue in Marco Island, Florida.

The DeepSeq Solution is based on the proven RainStorm microdroplet-based single molecule PCR technology and is optimised for both fresh frozen and FFPE tissue.

It delivers high specificity, accurate quantification, unbiased allelic representation, and enables the discovery of rare cancer mutations that represent as little as one percent of a heterogeneous tumour.

It runs on the RDT 1000 – an automated instrument that produces two million single molecule microdroplet-PCR reactions per sample in a single tube in less than one hour.